151 related articles for article (PubMed ID: 24563412)
1. Radiological monitoring of the treatment of solid tumors in practice.
Ganten MK; Ganten TM; Schlemmer HP
Rofo; 2014 May; 186(5):466-73. PubMed ID: 24563412
[TBL] [Abstract][Full Text] [Related]
2. A statistical simulation study finds discordance between WHO criteria and RECIST guideline.
Mazumdar M; Smith A; Schwartz LH
J Clin Epidemiol; 2004 Apr; 57(4):358-65. PubMed ID: 15135836
[TBL] [Abstract][Full Text] [Related]
3. Selection of response criteria for clinical trials of sarcoma treatment.
Schuetze SM; Baker LH; Benjamin RS; Canetta R
Oncologist; 2008; 13 Suppl 2():32-40. PubMed ID: 18434637
[TBL] [Abstract][Full Text] [Related]
4. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Lencioni R; Llovet JM
Semin Liver Dis; 2010 Feb; 30(1):52-60. PubMed ID: 20175033
[TBL] [Abstract][Full Text] [Related]
5. Tumor response evaluation in oncology: current update.
Shanbhogue AK; Karnad AB; Prasad SR
J Comput Assist Tomogr; 2010 Jul; 34(4):479-84. PubMed ID: 20657213
[TBL] [Abstract][Full Text] [Related]
6. Response criteria in oncologic imaging: review of traditional and new criteria.
Tirkes T; Hollar MA; Tann M; Kohli MD; Akisik F; Sandrasegaran K
Radiographics; 2013; 33(5):1323-41. PubMed ID: 24025927
[TBL] [Abstract][Full Text] [Related]
7. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
[TBL] [Abstract][Full Text] [Related]
8. [Radiological evaluation of tumor response in oncological studies (tumor response evaluation)].
Gebauer B; Bohnsack O; Riess H
Rofo; 2011 Aug; 183(8):695-703. PubMed ID: 21391174
[TBL] [Abstract][Full Text] [Related]
9. Imaging for oncologic staging and follow-up: review of current methods and novel approaches.
Cademartiri F; Luccichenti G; Maffei E; Fusaro M; Palumbo A; Soliani P; Sianesi M; Zompatori M; Crisi G; Krestin GR
Acta Biomed; 2008 Aug; 79(2):85-91. PubMed ID: 18788502
[TBL] [Abstract][Full Text] [Related]
10. [New guidelines to evaluate the response to treatment in solid tumors].
Duffaud F; Therasse P
Bull Cancer; 2000 Dec; 87(12):881-6. PubMed ID: 11174117
[TBL] [Abstract][Full Text] [Related]
11. Radiologic measurements of tumor response to treatment: practical approaches and limitations.
Suzuki C; Jacobsson H; Hatschek T; Torkzad MR; Bodén K; Eriksson-Alm Y; Berg E; Fujii H; Kubo A; Blomqvist L
Radiographics; 2008; 28(2):329-44. PubMed ID: 18349443
[TBL] [Abstract][Full Text] [Related]
12. Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0.
Chalian H; Töre HG; Horowitz JM; Salem R; Miller FH; Yaghmai V
Radiographics; 2011; 31(7):2093-105. PubMed ID: 22084190
[TBL] [Abstract][Full Text] [Related]
13. [New guidelines to evaluate the response to treatment "RECIST"].
Sasaki T
Gan To Kagaku Ryoho; 2000 Dec; 27(14):2179-84. PubMed ID: 11142160
[TBL] [Abstract][Full Text] [Related]
14. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
15. [Response criteria for malignant melanoma: RECIST and irRC].
Spiro J; Maintz D; Persigehl T
Radiologe; 2015 Feb; 55(2):127-35. PubMed ID: 25637198
[TBL] [Abstract][Full Text] [Related]
16. [Evaluating the effectiveness and timing of modification of anti-cancer drug therapies for colorectal cancer].
Miyamoto Y; Sakamoto Y; Ozaki N; Ishimoto T; Iwatsuki M; Baba Y; Iwagami S; Yoshida N; Watanabe M; Baba H
Gan To Kagaku Ryoho; 2012 Sep; 39(9):1326-9. PubMed ID: 22996767
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of tumour response to treatment with targeted therapies: standard or targeted criteria?].
Menu Y
Bull Cancer; 2007; 94(7 Suppl):F231-9. PubMed ID: 17965002
[TBL] [Abstract][Full Text] [Related]
18. RECIST revisited: a review of validation studies on tumour assessment.
Therasse P; Eisenhauer EA; Verweij J
Eur J Cancer; 2006 May; 42(8):1031-9. PubMed ID: 16616487
[TBL] [Abstract][Full Text] [Related]
19. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art.
de Mestier L; Dromain C; d'Assignies G; Scoazec JY; Lassau N; Lebtahi R; Brixi H; Mitry E; Guimbaud R; Courbon F; d'Herbomez M; Cadiot G
Endocr Relat Cancer; 2014 Jun; 21(3):R105-20. PubMed ID: 24351682
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
